客家妇女HPV感染型别分布的研究

目的:探讨人乳头瘤状病毒(Human Papillomavirus,HPV)在客家妇女人群中的型别分布情况,为客家地区HPV分子流行病学研究提供依据和检查出宫颈的癌前病变,达到在癌前病变时及早治疗,降低宫颈癌的发生率。方法:应用DNA杂交技术对2008年2月-2010年8月来医院就诊的11750例年龄在18—89岁的可疑患者进行21种HPV基因分型检测,其中包括16种高危亚型,5种低危压型。结果:11750例标本中阳性例教2386例,HPV阳性检出率为20.306%,其中高危感染率:93.822%,低危感染率:6.178%。结论:客家地区妇女HPV感染率高,主要为单一感染,多重感染有上升趋势;感染亚型主要是16、52和58型,体现了客家地区妇女感染HPV的特殊性。     

HPV亚型感染的地域分布与宫颈病变的关系

目的:探讨人乳头瘤病毒(HPV)亚型感染与宫颈病变的关系.方法:以桂北地区育龄妇女为研究对象,对门诊就诊的1086病例进行HPV分型检测和液基细胞学检查,对细胞学诊断≥ASCUS及HPV检测为阳性的病例进行阴道镜下宫颈组织活检.结果:①HPV检测阳性率为43.92%(477/1086);液基细胞学诊断≥ASCUS为31.49%(342/1086).在ASCUS、LSIL、HSIL、SCC中HPV的检出率分别为51.45%、70.27%、91.30%、100%.②细胞学诊断阳性≥LSIL(18.78%.204/1086)与组织学诊断阳性≥CIN Ⅰ(21.36%,232/1086)比较差异无统计学意义(χ2=2.250,P＞0.05),细胞学与组织学诊断符合率100%为SCC、80.23%为HSIL和90.98%为LSIL.组织学诊断CIN Ⅰ、CIN Ⅱ、CIN Ⅲ、SCC病变中HPV检出率以68.03%、81.67%、93.37%、100%依次递增.③1086例样本中HPV感染共检出21种亚型,低危型4种占17.19%、高危型17种占82.81%,随宫颈病变程度的增加,HPV亚型分布有所变化,低度病变组(CIN Ⅰ)以HPV16、58、18、56、11和52为常见类型;而高度病变组(CINⅡ～Ⅲ)以HPV16、58、18、56、33、52和11型为最常见.24例宫颈癌共检出6种高危亚型HPV,分别是HPV16、58、18、59、66和33型.HPV16亚型随宫颈病变级别加重感染率呈上升趋势(P＜0.0125).结论:桂北地区宫颈病变常见的HPV亚型是HPV16、58、18、56、33、52和11型,HPV16致癌性最强;HPV分型检测因其准确性高并能明确基因类型,联合液基细胞学和组织学更能有效地筛查宫颈病变细胞.为临床防治宫颈癌提供更可靠的科学依据.     

APTIMA HPV E6/E7 mRNA和MALDI-TOF-MS HPV基因分型检测宫颈高度病变效果评价

目的:以HC-Ⅱ法HPV DNA为对照,评价APTIMA法HPV E6/E7 mRNA检测(A-HPV)和MALDI-TOF-MS HPV分型检测技术(M-HPV)用于宫颈癌与癌前病变筛查的临床价值。方法:深圳市25~59岁、3年内未行宫颈癌筛查、未接受过子宫切除和盆腔放疗的2095例未孕妇女参加了本次筛查。医生于患者宫颈外口处直接收集2份宫颈脱落细胞标本,一份用于液基细胞学检查,一份用于HC-Ⅱ、A-HPV和M-HPV检测。宫颈细胞学≥ASCUS及3种方法 HPV检测任一阳性结果者均回叫行阴道镜下定点或四象限活检及宫颈管诊刮(ECC)。以病理诊断为标准评价各种HPV检测方法用于宫颈癌筛查的价值。结果:2095例研究对象中各项检测数据齐全者1970例。1970例患者的平均年龄为(35.89±7.655)岁。细胞学≥ASCUS者占6.4%(127/1970),CINⅡ+者占1.3%(26/1970),CINⅢ+者占0.76%(15/1970)。HC-Ⅱ、A-HPV和M-HPV总的HPV阳性率分别是19.4%、12.1%和14.8%,差异有统计学意义(P0.05)。HC-Ⅱ、A-HPV和M-HPV对检出CINⅡ+病变的敏感性分别为88.5%(95%CI为68.7~97.0)、100%(95%CI为84.0~100)和92.3%(95%CI为73.4~98.7),特异性分别为81.5(95%CI为79.7~83.2)、89.1%(95%CI为87.6~90.4)和86.3%(95%CI为84.6~87.8);A-HPV与HC-Ⅱ相比敏感性稍高(P0.05),M-HPV敏感性和HC-Ⅱ相同(P0.05),三者比较有统计学意义(P0.05)。结论:A-HPV和M-HPV用于宫颈癌筛查都有很好的敏感性和准确性,两者活检率明显低于HC-Ⅱ,可减少医疗负担和花费。HPV亚型分型和HPV E6/E7 mRNA结合有更好地预测宫颈癌患病风险的作用。     

广西沿海地区妇女宫颈癌患者人乳头瘤病毒（HPV）感染各亚型分布特点

目的探讨广西沿海地区妇女宫颈癌患者人乳头瘤状病毒（human papillomavirus,HPV）感染分布情况及主要型别,为广西沿海地区临床防治宫颈癌、研制适合该地区的预防性HPV疫苗提供理论依据。方法采用人乳头瘤病毒核酸扩增分型检测试剂盒方法,对76例广西沿海地区妇女经病理确诊宫颈癌患者的宫颈脱落细胞进行HPV基因分型检测。结果 76例宫颈癌患者中有69例HPV阳性,阳性率为90.8%,其中,HPV16感染率最高为56.5%,其他高危型的感染率从高到低依次为HPV18、33、58、52、53、31、45、35、39、51、56、66、68。低危型中HPV6型感染率最高为5.8%,其他低危型的感染率从高到低依次为HPV11、43、44。多重感染率为20.3%。正常对照组60例中有13例HPV阳性（21.7%）。其中,13例阳性标本中,HPV16感染率最高为30.8%,其他高危型HPV31、52、53感染率为15.4%,低危型HPV11、43、44感染率为7.7%。宫颈癌HPV阳性率明显高于正常对照组,差异有统计学意义（P〈0.005）。结论广西沿海地区妇女宫颈癌患者中以HPV16、18、33、58感染为主要型别,可能是广西沿海地区妇女宫颈癌较易感染的型别。     

HPV感染的宫颈病理学进展

<正>1与时俱进的CIN命名系统CIN已在全球通用了很多年,是大家耳熟能详的命名系统,但对其基本概念的诠释和英文翻译仍存在很多问题。同时,随着对HPV感染与宫颈癌发病机制的深入研究,整个命名系统的框架结构和一些基本名称的内在涵义也在悄然地发生着变化。     

宫颈细胞学正常的高危HPV感染妇女病理结局分析

目的:探讨宫颈细胞学正常但高危型HPV感染妇女的宫颈病理结局。方法:回顾分析2014年1月~12月就诊于湖北省妇幼保健院妇科门诊的30岁以上行宫颈细胞学+Cervista高危型HPV联合筛查妇女的临床资料,对细胞学正常但高危型HPV感染且行阴道镜检查的218例妇女取活组织检查,分析其病理结局。结果:218例患者中,宫颈病变占27.5%(60/218),其中宫颈低级别鳞状上皮内病变占11.0%(24/218),宫颈高级别鳞状上皮内病变占13.8%(30/218),宫颈浸润癌占2.8%(6/218)。HPV A9组感染共141例,其中CINⅡ/Ⅲ及以上病变21.3%(30/141),HPV A9组阳性与A9组阴性者比较,CINⅡ/Ⅲ及以上病变检出率比较,差异有统计学意义(P0.05)。结论:即使细胞学检查阴性,对宫颈高危型HPV检测及阳性结果尤其是A9组阳性,应高度重视,立即行阴道镜检查以早期发现宫颈高级别鳞状上皮内病变及宫颈浸润癌。     

应用核酸分子杂交技术检测女性CIN／VIN和浸润癌中的HPV

核酸分子杂交技术是目前检测女性下生殖道 CIN/VIN 和浸润癌病变组织中 HPV 特异性最强、检出率最高的一种方法。本文摘要介绍了四种分子杂交技术,即 Southern 杂交,斑点杂交、原位杂交和夹心杂交,并讨论了各种技术的优缺点。     

HPV在宫颈炎中的检测意义分析

目的 分析人乳头瘤病毒（HPV）在宫颈炎中的检测意义。方法 回顾性分析于本院行HPV分型检测的80例患者的临床资料,比较患者病理检查及HPV检测的结果,分析HPV分型在宫颈炎中的分布情况及HPV感染的影响因素。结果 HPV检测的敏感度为57.58%(19/33),特异度为74.47%(35/47),阳性预测值为0.613(19/31),阴性预测值为0.714(35/49)。宫颈炎HPV感染以HPV52(52.6%)、HPV16(26.3%)、HPV18(10.5%)、HPV53(5.3%)、HPV58(5.3%)为主。存在生殖道炎症的人群为HPV感染的高发群体,其感染HPV的概率为64.52%,高于不存在生殖道炎症人群的24.49%,差异有统计学意义（P<0.05）。不同年龄人群间的HPV感染率比较,差异无统计学意义（P>0.05）。结论HPV分型检测对宫颈炎有较高的诊断敏感度及特异度,HPV52、16、18、53、58为宫颈炎主要感染的HPV亚型,存在生殖道炎症为HPV感染的主要原因。     

宫颈癌机会性筛查人群中高危型HPV感染状况及其与宫颈病变关系的研究

目的:分析宫颈癌机会性筛查人群中高危型HPV感染情况及其与宫颈病变的关系。方法:统计2015年6月至2016年11月于北京大学第三医院行宫颈癌机会性筛查人群中HPV 16型、18型及其他12种HPV亚型的阳性率,计算高危型HPV阳性转诊阴道镜人群中发生CINⅡ及以上(CINⅡ~+)的比率及CINⅡ~+人群中HPV的感染构成情况。结果:宫颈癌机会性筛查人群中,高危型HPV总阳性率为19.0%,HPV 16阳性率为5.0%,HPV 18阳性率为1.6%,其他12种HPV阳性率为15.2%。HPV 16阳性、HPV 18阳性及其他12种HPV阳性患者TCT分流检测≥ASCUS者均转诊阴道镜病理活检,其发生CINⅡ~+的比率依次为55.2%、35.5%及38.9%;发生CINⅢ及以上(CINⅢ~+)的比率依次为25.3%、7.7%及6.9%。CINⅡ~+中45.0%为其他12种HPV感染、46.3%为HPV16感染、8.7%为HPV 18感染,其余病例为HPV阴性。结论:宫颈癌机会性筛查人群中,CINⅡ~+患者HPV 18阳性所占比率较低,其他12种HPV阳性所占比率高。需对各亚型阳性率进行细致分型以协助评估发病风险。转诊阴道镜人群中,HPV 18阳性者及其他12种HPV阳性患者TCT检查为ASCUS/LSIL者发生CINⅡ~+风险相对较低,可考虑通过行分流检测以提高筛查的特异性。     

保妇康栓治疗宫颈HPV感染疗效分析

<正>2009年4月至2011年3月我院使用中药保妇康栓阴道放药治疗宫颈HPV感染,现就临床资料报告如下。1资料与方法1.1一般资料上述期间在我院妇科门诊确诊的宫颈HPV感染患者119例,受试者均接受宫颈LBP检测(宫颈液基细胞学检测,广州必安平医药公司)及HPV高危型DNA检测     

Human papillomavirus genotype as a prognostic factor in carcinoma of the uterine cervix

The clinical implications of specific human papillomavirus (HPV) types in invasive cervical carcinomas are only now beginning to be appreciated. The objective of this study was to determine the clinical implications and prognostic value of the HPV genotype in cervical carcinomas. In this study, we employed an HPV DNA chip to detect the type-specific sequence of HPV from cervical swabs taken from women with biopsy-proven neoplastic lesions of the cervix. We divided the patients into four groups: HPV-negative, HPV-16-related, HPV-18-related, and intermediate risk type-related. Associations with clinicopathologic data (stage, histologic type, lymph node status, parametrial invasion, lymphvascular space invasion, tumor size, vaginal involvement) and overall survival were assessed. HPV DNA was detected in 81.4% of the patients, and 19.0% harbored multiple HPV variants. HPV-16-related was the predominant type and was detected in 47.4% (46/97) of the patients. The HPV-16-related types were detected more frequently in patients with squamous cell carcinomas, whereas the HPV-18-related types were more prevalent in cases of adenocarcinomas and adenosquamous carcinomas (P < 0.05). Otherwise, no significant correlations were detected between the HPV genotype and any other clinicopathologic parameters. After a median follow-up of 30 months, the 5-year survival rate was lower in the HPV-18-related patients, but this difference was not found to be statistically significant, according to the results of the log-rank test. We conclude that neither the presence nor type of HPV DNA bears any prognostic significance in cases of cervical carcinoma.     

Human papillomavirus in the oral mucosa of women with genital human papillomavirus lesions

OBJECTIVES: Human papillomavirus (HPV) infection is one of the most common sexually transmitted diseases worldwide. We determined the frequency of HPV in the oral cavity of women with and without genital HPV lesions. MATERIAL AND METHODS: All patients were seen at the Department of Gynecology, Women's Health Center and the State University of Campinas, Sao Paulo, Brazil and submitted to a general physical and gynecological examination plus an evaluation of the oral cavity. Detailed histories investigated their sexual practices. HPV in the oral cavity was determined by polymerase chain reaction using consensus primers in 70 women presenting with histopathology-confirmed clinical HPV lesions in the genital region and 70 women negative by gynecological, colposcopic and cytological examination for clinical or subclinical HPV lesions. RESULTS: Oral HPV was detected in 29 (20.7%) of the subjects. Among the positive women, 26 (89.7%) were also positive for genital HPV as opposed to only 3 (2.7%) who were genital HPV-negative (p < 0.0001). The overall prevalence of HPV in the oral cavity of patients with and without genital HPV was 37.1 and 4.3%, respectively, (p < 0.0001). The presence of oral HPV was unrelated to the practice of fellatio (22% versus 19%). CONCLUSION: Patients with HPV genital infection have a greater frequency of HPV in their oral mucosa.     

Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia

Multicenter international phase III clinical trials using multivalent human papillomavirus (HPV) vaccines for cervical cancer (CC) prevention are underway. As HPV immunity is type specific, defining HPV genotype prevalence in different regions to ascertain whether predominant types differ geographically is considerably important prior to vaccine implementation. This study aimed to define HPV genotypes present in CC and high-grade dysplasia among women in Melbourne, Australia. HPV genotype analysis of a cross section of women in Melbourne with cervical dysplasia/cancer was performed. A total of 493 cervical biopsies from patients being treated for moderate (n= 122) or severe (n= 180) cervical intraepithelial neoplasia (CIN II/III) or CC (n= 191) were tested for HPV genotypes using the PGMY09/11 primer system and line blot assay. HPV detection rates were 63.9%, 72.8%, and 86.9% in CIN II, CIN III, and CC biopsies, respectively. The most prevalent HPV genotypes among CC biopsies were HPV-16 (52.9%), HPV-18 (18.3%), HPV-45 (6.3%), HPV-39 (3.1%), and HPV-73 (2.6%). Multiple HPV infections, comprising two to five types, were identified in 14.4% of biopsies, being significantly fewer (5.2%) among CC biopsies (P < 0.0001). These results indicate that the two most prevalent CC-associated HPV genotypes in Australia parallel those described internationally, with type variations thereafter.     

Human papillomavirus genotyping using HPV DNA chip analysis in Korean women

This study was designed to investigate the genotypes of human papillomavirus (HPV) in Korean women who had abnormal cervical cytology and to evaluate the clinical accuracy of HPV DNA chip analysis for the diagnosis of cervical neoplasia. Liquid-based cytology preparations, HPV DNA chip analysis, and cervical biopsy were performed in 2358 women. High-risk HPV was identified in 23.5% of 1650 histologically confirmed normal samples (including cervicitis and squamous metaplasia) and in 81.8% of 708 samples with cervical intraepithelial neoplasia (CIN) and carcinoma (P<0.01). The major prevalent high-risk HPV genotypes in 381 samples of CIN II/III were HPV-16, -58, -33, and -31, in order of prevalence rate (average overall, 78.0%), and HPV-16, -18, -58, and -33 (average overall, 81.2%) in 133 samples of squamous cell carcinoma (SCC). The infection rate of HPV-16 was significantly higher than that of other high-risk HPV genotypes in all normal, CIN, and SCC cases (P < 0.01) and increased with more advanced squamous cervical lesions (P<0.01). The detection accuracy of high-risk HPV using HPV DNA chip analysis for CIN II or worse was as follows: sensitivity 84% (81-87%), specificity 72% (70-74%), positive predictive value 47% (44-50%), and negative predictive value 94% (92-95%). These results suggest that HPV DNA chip analysis may be a reliable diagnostic tool for the detection of cervical neoplasia and that there are geographic differences in the distribution of high-risk HPV genotypes.     

Human papillomavirus in cervical smears taken from women wearing an intrauterine contraceptive device

Summary Cervical cells were screened for human papillomavirus (HPV) infections by in situ filter hybridization in 108 patients wearing intrauterine contraceptive devices. The cells were tested for the presence of HPV 6, 11, 16, 18. DNA. In 86 cases (79.6%) no reactions were obtained with³² P-labeled HPV DNA probes. 22 smears (20.3%) were positive for HPV: type 6 and 11 sequences were demonstrated in 17 cases (3 of them carried both). 4 smears hybridized with the probe for oncogenic HPV 16 and one with that for oncogenic type 18. All these five patients had normal smears and no abnormality on colposcopy.